文章摘要
汪佩林,徐文付,徐双云,常甄瑱,姚 超.小儿肺热咳喘口服液联合布地奈德雾化吸入治疗小儿喘息性支气管炎的疗效及改善机体炎症反应和免疫力的效果研究[J].,2023,(6):1165-1168
小儿肺热咳喘口服液联合布地奈德雾化吸入治疗小儿喘息性支气管炎的疗效及改善机体炎症反应和免疫力的效果研究
Study on the Therapeutic Effect of Xiaoer Feire Kechuan Oral Liquid Combined with Budesonide Aerosol Inhalation in Treating Children with Asthmatic Bronchitis and Improving the Body's Inflammatory Response and Immunity
投稿时间:2022-08-08  修订日期:2022-08-31
DOI:10.13241/j.cnki.pmb.2023.06.033
中文关键词: 小儿肺热咳喘口服液  布地奈德  儿童  喘息性支气管炎  疗效  炎症反应  免疫力
英文关键词: Xiaoer Feire Kechuan oral liquid  Budesonide  Children  Asthmatic bronchitis  Therapeutic effect  Inflammatory response  Immunity
基金项目:安徽省卫计委医学科研项目(16zc044)
作者单位E-mail
汪佩林 合肥市第二人民医院(安徽医科大学附属合肥医院)儿科 安徽 合肥 230011 wpl510057308@163.com 
徐文付 合肥市第二人民医院(安徽医科大学附属合肥医院)儿科 安徽 合肥 230011  
徐双云 合肥市第二人民医院(安徽医科大学附属合肥医院)儿科 安徽 合肥 230011  
常甄瑱 合肥市第二人民医院(安徽医科大学附属合肥医院)儿科 安徽 合肥 230011  
姚 超 合肥市第二人民医院(安徽医科大学附属合肥医院)儿科 安徽 合肥 230011  
摘要点击次数: 864
全文下载次数: 501
中文摘要:
      摘要 目的:探讨小儿喘息性支气管炎经布地奈德雾化吸入、小儿肺热咳喘口服液联合治疗后的疗效及改善机体炎症反应和免疫力的效果。方法:选取2018年1月~2022年6月期间我院收治的60例小儿喘息性支气管炎作为研究对象,根据随机数字表法分为对照组(n=30,接受布地奈德单药治疗)和观察组(n=30,接受布地奈德联合小儿肺热咳喘口服液治疗)。对比两组临床疗效、临床症状改善情况、T淋巴细胞亚群、炎症因子和不良反应。结果:与对照组73.33%(22/30)比较,观察组临床总有效率93.33%(28/30)明显升高(P<0.05)。与对照组相比,观察组热退时间和哮鸣音/咳嗽/喘息消失时间更短(P<0.05)。与对照组相比,观察组治疗5 d后CD3+、CD4+、CD4+/CD8+更高,CD8+更低(P<0.05)。与对照组相比,观察组治疗5 d后C反应蛋白(CRP)、白介素-6(IL-6)、降钙素原(PCT)更低(P<0.05)。两组均未出现明显的药物不良反应。结论:小儿喘息性支气管炎采用小儿肺热咳喘口服液联合布地奈德雾化吸入治疗,可使症状缓解时间缩短,降低患儿炎症因子水平,提高其免疫力。
英文摘要:
      ABSTRACT Objective: To investigate the therapeutic effect of budesonide aerosol inhalation combined with Xiaoer Feire Kechuan oral liquid in the treatment of children with asthmatic bronchitis and the effect of improving the body's inflammatory response and immunity. Methods: 60 children with asthmatic bronchitis who were admitted to our hospital from January 2018 to June 2022 were selected as research objects. According to the random number table method, they were divided into the control group (n=30, treated with budesonide monotherapy) and the observation group (n=30, treated with budesonide combined with Xiaoer Feire Kechuan oral liquid). The clinical efficacy, improvement of clinical symptoms, T lymphocyte subsets, inflammatory factors and adverse reactions were compared between the two groups. Results: Compared with 73.33% (22/30) of the control group, the total clinical effective rate 93.33% (28/30) in the observation group was significantly higher(P<0.05).Compared with control group, the heat withdrawal time and wheezing sound/cough /wheezing disappearance time of observation group were shorter (P<0.05). Compared with control group, CD3+, CD4+, CD4+/CD8+ of observation group at 5 d after treatment were higher, and CD8+ was lower (P<0.05). Compared with control group, C-reactive protein (CRP), interleukin-6 (IL-6) and procalcitonin (PCT) of observation group at 5 d after treatment were lower (P<0.05). There were no obvious adverse drug reactions in the two groups. Conclusion: Children's asthmatic bronchitis can be treated with Xiaoer Feire Kechuan oral liquid combined with budesonide aerosol inhalation, which can shorten the time for symptom relief, reduce the level of inflammatory factors in children, and improve their immunity.
查看全文   查看/发表评论  下载PDF阅读器
关闭